| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9340987 | Urologic Oncology: Seminars and Original Investigations | 2005 | 7 Pages |
Abstract
This Phase II trial with a long-term follow-up revealed that some patients with hormone refractory prostate cancer could obtain durable disease response and long survival with an oral etoposide and estramustine combination regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alfredo Berruti, Enrica Fara, Marcello Tucci, Roberto Tarabuzzi, Alessandra Mosca, Carlo Terrone, Gabriella Gorzegno, Giuseppe Fasolis, Marco Tampellini, Francesco Porpiglia, Marinella De Stefanis, Dario Fontana, Oscar Bertetto, Luigi Dogliotti,